This research study is for men who have a diagnosis of prostate cancer and have been selected by their physician to receive Pluvicto to treat their cancer.
   
This is a feasibility study that evaluates a software technology called TRAQinform Theranostics. The purpose of this study is to learn if more information (analysis) from the TRAQinform Theranostics software changes a physician’s understanding of treatment planning and how prostate cancer is responding to Pluvicto. The U.S. Food and Drug Administration (FDA) has not approved TRAQinform Theranostics for this specific disease, but it has been approved for other uses. It is considered investigational in this study.
   
TRAQinform Theranostics software automatically compares and analyzes imaging scans from the start of a participant’s treatment and during their treatment to provide more information to their physician. More information includes 1) visualization of individual lesions, 2) understanding which lesions are responding to treatment, and 3) understanding if critical organs are affected by the treatment.
   
For participants in this study, two Positron Emission Tomography and Computed Tomography (PET/CT) scans will be ordered and two diagnostic CTs will be ordered. The first PET/CT and diagnostic CT will be done before a participant starts Pluvicto and the second PET/CT and diagnostic CT will be done around 12 weeks after starting Pluvicto.

Participation in this study will last about 12 weeks.